BCTX — BriaCell Therapeutics Corp. Dilution Risk Tracker

BriaCell Therapeutics Corp. (BCTX) has a DilutionScore of 66/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 13, 2026, updated from SEC EDGAR data.

The most significant dilution vector for BCTX is its shelf registration capacity of $25.0M. A shelf registration (typically an S-3 filing) gives a company pre-approved access to raise capital quickly without a traditional roadshow. The registered amount represents the maximum that can be raised — not necessarily what will be raised — but active shelves combined with tight cash positions are the pattern DilutionWatch monitors most closely. Cash runway is a key watch item: BCTX has approximately 11 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for BCTX in real-time, scanning EDGAR every 60 seconds. A recent S-3 or registration statement filing appears in BCTX's filing history — this warrants monitoring for subsequent prospectus supplements (Form 424B), which indicate active capital raising. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for BCTX alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.